View ValuationVital Chemtech 将来の成長Future 基準チェック /06現在、 Vital Chemtechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長18.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 41% per year over the past 5 years. High level of non-cash earnings (41% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹1.24b market cap, or US$13.1m).Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹40.95, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 53% over the past three years.New Risk • Mar 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹900.6m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 41% per year over the past 5 years. High level of non-cash earnings (41% accrual ratio). Market cap is less than US$10m (₹900.6m market cap, or US$9.76m).Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹39.90, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 53% over the past three years.お知らせ • Nov 14Vital Chemtech Limited to Report First Half, 2026 Results on Nov 14, 2025Vital Chemtech Limited announced that they will report first half, 2026 results on Nov 14, 2025New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (35% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (₹1.49b market cap, or US$16.8m).Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹64.30, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 13% over the past year.Reported Earnings • Sep 10Full year 2025 earnings released: EPS: ₹1.93 (vs ₹27.63 loss in FY 2024)Full year 2025 results: EPS: ₹1.93 (up from ₹27.63 loss in FY 2024). Revenue: ₹1.34b (up 36% from FY 2024). Net income: ₹40.6m (up ₹53.6m from FY 2024). Profit margin: 3.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue.お知らせ • Sep 01Vital Chemtech Limited, Annual General Meeting, Sep 27, 2025Vital Chemtech Limited, Annual General Meeting, Sep 27, 2025, at 14:00 Indian Standard Time.New Risk • Jun 05New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 13% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (35% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.56b market cap, or US$18.2m).New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.65b market cap, or US$19.4m).New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₹1.76b market cap, or US$20.6m).分析記事 • Mar 14Would Vital Chemtech (NSE:VITAL) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Sep 13Vital Chemtech Limited, Annual General Meeting, Sep 30, 2024Vital Chemtech Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.分析記事 • Sep 06Vital Chemtech's (NSE:VITAL) Dividend Will Be ₹0.50Vital Chemtech Limited's ( NSE:VITAL ) investors are due to receive a payment of ₹0.50 per share on 30th of October...Declared Dividend • Sep 05Dividend of ₹0.50 announcedDividend of ₹0.50 is the same as last year. Ex-date: 13th September 2024 Payment date: 30th October 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (16% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.分析記事 • Aug 16It's Down 26% But Vital Chemtech Limited (NSE:VITAL) Could Be Riskier Than It LooksVital Chemtech Limited ( NSE:VITAL ) shareholders won't be pleased to see that the share price has had a very rough...New Risk • Jul 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹2.32b market cap, or US$27.8m).分析記事 • Jun 21Vital Chemtech Limited (NSE:VITAL) Screens Well But There Might Be A CatchIt's not a stretch to say that Vital Chemtech Limited's ( NSE:VITAL ) price-to-sales (or "P/S") ratio of 2x right now...New Risk • Jun 14New major risk - Revenue and earnings growthEarnings have declined by 4.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.78b market cap, or US$21.4m).お知らせ • May 31Vital Chemtech Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2024Vital Chemtech Limited Recommended a Final Dividend of INR 0.50/- (Fifty Paisa Only) per equity share, face value INR 10/- per equity share (i.e. 5 % of face value) for the financial year ended on March 31, 2024, subject To Approve the members at the ensuing Annual General Meeting. Final Dividend, if approved by the members, will be paid/dispatched after the Annual General Meeting.New Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹2.01b market cap, or US$24.2m).Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹91.35, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 31x in the Chemicals industry in India. Total loss to shareholders of 2.3% over the past year.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.35, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 13% over the past year.分析記事 • Mar 19Here's Why Vital Chemtech (NSE:VITAL) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹99.85, the stock trades at a trailing P/E ratio of 62.6x. Average trailing P/E is 29x in the Chemicals industry in India. Total loss to shareholders of 22% over the past year.Reported Earnings • May 24Full year 2023 earnings released: EPS: ₹4.50 (vs ₹12.99 in FY 2022)Full year 2023 results: EPS: ₹4.50 (down from ₹12.99 in FY 2022). Revenue: ₹1.17b (down 18% from FY 2022). Net income: ₹80.5m (down 45% from FY 2022). Profit margin: 6.9% (down from 10% in FY 2022). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹111, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 20x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹94.45, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 19x in the Chemicals industry in India.Recent Insider Transactions • Apr 02Chairman & MD recently bought ₹2.8m worth of stockOn the 31st of March, Vipul Bhatt bought around 36k shares on-market at roughly ₹76.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vipul's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹78.60, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 19x in the Chemicals industry in India.お知らせ • Nov 24Vital Chemtech Limited Announces Board ChangesVital Chemtech Limited at its board meeting held on November 22, 2022 approved the resignation of Ms. puja paras Mehta,Company Secretary & Compliance Officer, at the Close of business hours of November 21, 2022. The company also approved the appointment of Mr. Utsav Sudhir Trivedi. DOB:- 086 June, 1994. Date of appointment: November 22, 2022. Term of Appointment: Appointed as Company Secretary & Compliance officer of the company. Education Qualification: Company Secretary (C.S.).LLB & B.Com. He is an Associate Member of institute of Company Secretaries of India having experience of Months and Pre-qualification experience of 2 years and is well versed with knowledge of Corporate Law, Corporate Governance & SEBI laws and regulations.Reported Earnings • Nov 20First half 2023 earnings releasedFirst half 2023 results: EPS: ₹3.48. Net income: ₹60.8m (up ₹60.8m from 1H 2022).Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Whole Time Director Sangeeta Bhatt is the most experienced director on the board, commencing their role in 2022. Independent Director Deepakkumar Chaubisa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vital Chemtech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:VITAL - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20251,32531-539-111N/A6/30/20251,33236-468-25N/A3/31/20251,33941-39662N/A12/31/20241,24216N/AN/AN/A9/30/20241,144-8-16845N/A6/30/20241,064-11-11892N/A3/31/2024983-13-68140N/A12/31/20231,02113N/AN/AN/A9/30/20231,05938-36140N/A6/30/20231,11359-8722N/A3/31/20231,16781-178-83N/A12/31/202291386N/AN/AN/A9/30/20221,514158N/AN/AN/A6/30/20221,473152N/AN/AN/A3/31/202257679-219-132N/A3/31/2021474293161N/A3/31/2020412112837N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VITALの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VITALの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VITALの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VITALの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VITALの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VITALの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 15:51終値2026/06/23 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vital Chemtech Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 41% per year over the past 5 years. High level of non-cash earnings (41% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹1.24b market cap, or US$13.1m).
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹40.95, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 53% over the past three years.
New Risk • Mar 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹900.6m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 41% per year over the past 5 years. High level of non-cash earnings (41% accrual ratio). Market cap is less than US$10m (₹900.6m market cap, or US$9.76m).
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹39.90, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 53% over the past three years.
お知らせ • Nov 14Vital Chemtech Limited to Report First Half, 2026 Results on Nov 14, 2025Vital Chemtech Limited announced that they will report first half, 2026 results on Nov 14, 2025
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (35% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (₹1.49b market cap, or US$16.8m).
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹64.30, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 13% over the past year.
Reported Earnings • Sep 10Full year 2025 earnings released: EPS: ₹1.93 (vs ₹27.63 loss in FY 2024)Full year 2025 results: EPS: ₹1.93 (up from ₹27.63 loss in FY 2024). Revenue: ₹1.34b (up 36% from FY 2024). Net income: ₹40.6m (up ₹53.6m from FY 2024). Profit margin: 3.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue.
お知らせ • Sep 01Vital Chemtech Limited, Annual General Meeting, Sep 27, 2025Vital Chemtech Limited, Annual General Meeting, Sep 27, 2025, at 14:00 Indian Standard Time.
New Risk • Jun 05New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 13% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (35% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.56b market cap, or US$18.2m).
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.65b market cap, or US$19.4m).
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₹1.76b market cap, or US$20.6m).
分析記事 • Mar 14Would Vital Chemtech (NSE:VITAL) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Sep 13Vital Chemtech Limited, Annual General Meeting, Sep 30, 2024Vital Chemtech Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.
分析記事 • Sep 06Vital Chemtech's (NSE:VITAL) Dividend Will Be ₹0.50Vital Chemtech Limited's ( NSE:VITAL ) investors are due to receive a payment of ₹0.50 per share on 30th of October...
Declared Dividend • Sep 05Dividend of ₹0.50 announcedDividend of ₹0.50 is the same as last year. Ex-date: 13th September 2024 Payment date: 30th October 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (16% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
分析記事 • Aug 16It's Down 26% But Vital Chemtech Limited (NSE:VITAL) Could Be Riskier Than It LooksVital Chemtech Limited ( NSE:VITAL ) shareholders won't be pleased to see that the share price has had a very rough...
New Risk • Jul 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹2.32b market cap, or US$27.8m).
分析記事 • Jun 21Vital Chemtech Limited (NSE:VITAL) Screens Well But There Might Be A CatchIt's not a stretch to say that Vital Chemtech Limited's ( NSE:VITAL ) price-to-sales (or "P/S") ratio of 2x right now...
New Risk • Jun 14New major risk - Revenue and earnings growthEarnings have declined by 4.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.78b market cap, or US$21.4m).
お知らせ • May 31Vital Chemtech Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2024Vital Chemtech Limited Recommended a Final Dividend of INR 0.50/- (Fifty Paisa Only) per equity share, face value INR 10/- per equity share (i.e. 5 % of face value) for the financial year ended on March 31, 2024, subject To Approve the members at the ensuing Annual General Meeting. Final Dividend, if approved by the members, will be paid/dispatched after the Annual General Meeting.
New Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹2.01b market cap, or US$24.2m).
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹91.35, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 31x in the Chemicals industry in India. Total loss to shareholders of 2.3% over the past year.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.35, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 13% over the past year.
分析記事 • Mar 19Here's Why Vital Chemtech (NSE:VITAL) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹99.85, the stock trades at a trailing P/E ratio of 62.6x. Average trailing P/E is 29x in the Chemicals industry in India. Total loss to shareholders of 22% over the past year.
Reported Earnings • May 24Full year 2023 earnings released: EPS: ₹4.50 (vs ₹12.99 in FY 2022)Full year 2023 results: EPS: ₹4.50 (down from ₹12.99 in FY 2022). Revenue: ₹1.17b (down 18% from FY 2022). Net income: ₹80.5m (down 45% from FY 2022). Profit margin: 6.9% (down from 10% in FY 2022). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹111, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 20x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹94.45, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 19x in the Chemicals industry in India.
Recent Insider Transactions • Apr 02Chairman & MD recently bought ₹2.8m worth of stockOn the 31st of March, Vipul Bhatt bought around 36k shares on-market at roughly ₹76.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vipul's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹78.60, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 19x in the Chemicals industry in India.
お知らせ • Nov 24Vital Chemtech Limited Announces Board ChangesVital Chemtech Limited at its board meeting held on November 22, 2022 approved the resignation of Ms. puja paras Mehta,Company Secretary & Compliance Officer, at the Close of business hours of November 21, 2022. The company also approved the appointment of Mr. Utsav Sudhir Trivedi. DOB:- 086 June, 1994. Date of appointment: November 22, 2022. Term of Appointment: Appointed as Company Secretary & Compliance officer of the company. Education Qualification: Company Secretary (C.S.).LLB & B.Com. He is an Associate Member of institute of Company Secretaries of India having experience of Months and Pre-qualification experience of 2 years and is well versed with knowledge of Corporate Law, Corporate Governance & SEBI laws and regulations.
Reported Earnings • Nov 20First half 2023 earnings releasedFirst half 2023 results: EPS: ₹3.48. Net income: ₹60.8m (up ₹60.8m from 1H 2022).
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Whole Time Director Sangeeta Bhatt is the most experienced director on the board, commencing their role in 2022. Independent Director Deepakkumar Chaubisa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.